BioNexus Gene Lab Corp. Assets, Fair Value Adjustment
BioNexus Gene Lab Corp. (BGLC) reported Assets, Fair Value Adjustment of $8.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:AssetsFairValueAdjustment · last filed 2026-08-14
- BioNexus Gene Lab Corp. assets, fair value adjustment for the quarter ending 2026-06-30 was -$313.71K.
- BioNexus Gene Lab Corp. assets, fair value adjustment for the quarter ending 2026-03-31 was $9.04M, a 4.64% decline year-over-year.
- BioNexus Gene Lab Corp. assets, fair value adjustment for the quarter ending 2025-12-31 was $1.63M.
- BioNexus Gene Lab Corp. assets, fair value adjustment for the quarter ending 2025-09-30 was -$1.80M.
- BioNexus Gene Lab Corp. assets, fair value adjustment for fiscal 2024 was $10.43M, a 8.47% decline from fiscal 2023.
- BioNexus Gene Lab Corp. assets, fair value adjustment for fiscal 2023 was $11.40M.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$313.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.73M 10-Q · filed 2026-08-14 | $10.36M derived: sum of 3 quarters · filed 2026-08-14 | $8.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $9.04M 10-Q · filed 2026-05-15 | $10.67M derived: sum of 2 quarters · filed 2026-08-14 | $8.87M derived: sum of 3 quarters · filed 2026-08-14 | $8.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.63M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | -$168.42K derived: sum of 2 quarters · filed 2026-08-14 | -$227.16K derived: sum of 3 quarters · filed 2026-08-14 | $9.25M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.86M derived: sum of 2 quarters · filed 2025-11-14 | $7.62M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$58.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $9.42M 10-Q · filed 2025-08-18 | ||
| 2025-03-31 | $9.48M 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $10.43M 10-K · filed 2026-04-14 | |||
| 2023-12-31 | $11.40M 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |